192 related articles for article (PubMed ID: 20157701)
1. Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study.
Gudbjornsson B; Thorsteinsson SB; Sigvaldason H; Einarsdottir R; Johannsson M; Zoega H; Halldorsson M; Thorgeirsson G
Eur J Clin Pharmacol; 2010 Jun; 66(6):619-25. PubMed ID: 20157701
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
Huang WF; Hsiao FY; Tsai YW; Wen YW; Shih YT
Drug Saf; 2006; 29(3):261-72. PubMed ID: 16524325
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
[TBL] [Abstract][Full Text] [Related]
4. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.
Lévesque LE; Brophy JM; Zhang B
CMAJ; 2006 May; 174(11):1563-9. PubMed ID: 16670396
[TBL] [Abstract][Full Text] [Related]
5. Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk.
Lee YH; Ji JD; Song GG
Rheumatol Int; 2007 Mar; 27(5):477-82. PubMed ID: 17051359
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
[TBL] [Abstract][Full Text] [Related]
7. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
[TBL] [Abstract][Full Text] [Related]
8. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Chen LC; Ashcroft DM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):762-72. PubMed ID: 17457957
[TBL] [Abstract][Full Text] [Related]
9. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
Motsko SP; Rascati KL; Busti AJ; Wilson JP; Barner JC; Lawson KA; Worchel J
Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554
[TBL] [Abstract][Full Text] [Related]
10. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Kimmel SE; Berlin JA; Reilly M; Jaskowiak J; Kishel L; Chittams J; Strom BL
Ann Intern Med; 2005 Feb; 142(3):157-64. PubMed ID: 15684203
[TBL] [Abstract][Full Text] [Related]
11. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
12. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
[TBL] [Abstract][Full Text] [Related]
13. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
14. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
Kasliwal R; Layton D; Harris S; Wilton L; Shakir SA
Drug Saf; 2005; 28(9):803-16. PubMed ID: 16119973
[TBL] [Abstract][Full Text] [Related]
15. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S
Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
[TBL] [Abstract][Full Text] [Related]
16. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
17. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
18. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
[TBL] [Abstract][Full Text] [Related]
19. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
Cunnington M; Webb D; Qizilbash N; Blum D; Mander A; Funk MJ; Weil J
Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):601-8. PubMed ID: 18383442
[TBL] [Abstract][Full Text] [Related]
20. [What do we know about the cardiovascular toxicity of the NSAIDs?].
Sibilia J; Deray G; Montalescot G
Presse Med; 2006 Sep; 35(9 Spec No 1):1S11-23. PubMed ID: 17078591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
